Sang-Woo Park
Director Ejecutivo en NKMAX CO., LTD. .
Fortuna: 794 962 $ al 30/04/2024
Cargos activos de Sang-Woo Park
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| NKMAX CO., LTD. | Director Ejecutivo | 31/03/2023 | - |
| Presidente | 14/01/2002 | - | |
| Fundador | 14/01/2002 | - | |
| ATGen America, Inc. | Director Ejecutivo | 01/02/2014 | - |
| Presidente | 01/02/2014 | - | |
| ATGen Canada, Inc. | Director Ejecutivo | 01/09/2013 | - |
| Presidente | 01/09/2013 | - | |
Atgen H&D
 Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Director Ejecutivo | 01/01/2016 | - |
NKMAX Co., Ltd.
 NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Presidente | 01/01/2002 | - |
| Director Ejecutivo | 01/01/2002 | - | |
| Fundador | 01/01/2002 | - | |
| Director/Miembro de la Junta | 01/01/2002 | - | |
| Nkmax H&D Co. Ltd. | Director Ejecutivo | 01/06/2016 | - |
| Presidente | 01/06/2016 | - | |
coAsia Biotech Corp.
 coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Director Ejecutivo | 01/04/2016 | - |
| Presidente | 01/04/2016 | - | |
| Atgen Japan | Director Ejecutivo | 01/09/2017 | - |
| Presidente | 01/09/2017 | - | |
| Nkmax Japan, Inc. | Director Ejecutivo | 01/11/2017 | - |
| Presidente | 01/11/2017 | - |
Historial de carrera de Sang-Woo Park
Antiguos cargos conocidos de Sang-Woo Park.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░ ░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Formación de Sang-Woo Park.
| Korea University | Undergraduate Degree |
Estadísticas
Internacional
| Corea del Sur | 7 |
| Estados Unidos | 3 |
| Japón | 3 |
Operativa
| Chief Executive Officer | 11 |
| Chairman | 10 |
| Director/Board Member | 4 |
Sectorial
| Health Technology | 6 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| J WAY CO., LTD. | Consumer Services |
| NKMAX CO., LTD. | Health Technology |
| Empresas privadas | 9 |
|---|---|
| ATGen America, Inc. | |
| ATGen Canada, Inc. | |
Atgen H&D
Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Health Technology |
NKMAX Co., Ltd.
NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Health Technology |
| Nkmax H&D Co. Ltd. | |
coAsia Biotech Corp.
coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Health Technology |
| Atgen Japan | |
NKGen Biotech, Inc.
 NKGen Biotech, Inc. BiotechnologyHealth Technology NKGen Biotech, Inc. is a biotechnology company which engages in harnessing the immune system through natural killer cell therapies. It develops a proprietary stabilizing peptide, monoclonal antibodies, and recombinant proteins for research use. The company was founded in 2002 and is headquartered in Santa Ana, CA. | Health Technology |
| Nkmax Japan, Inc. |
- Bolsa de valores
- Insiders
- Sang-Woo Park
- Experiencia